合并症而非患者年龄与维得利珠单抗和乌司奴单抗治疗的炎症性肠病患者安全性结局受损相关:一项前瞻性多中心队列研究
这项前瞻性多中心队列研究纳入203例维得利珠单抗和207例乌司奴单抗治疗的炎症性肠病患者,评估年龄和合并症(查尔森合并症指数,CCI)与安全性和有效性结局的关联。结果显示CCI独立与维得利珠单抗组任何感染和住院相关,与乌司奴单抗组住院相关;CCI与有效性无关,年龄与任何结局无关。结论强调合并症评估和安全性监测的重要性。
要点
- 维得利珠单抗治疗中,CCI独立与任何感染(OR 1.387)和住院(OR 1.586)相关。
- 乌司奴单抗治疗中,CCI独立与住院(OR 1.621)相关。
- CCI与有效性结局无关,年龄与任何结局均无关。
核心结论
- 合并症而非年龄与两种治疗中住院风险增加相关,并与维得利珠单抗治疗中任何感染相关。
- 这强调了炎症性肠病患者合并症评估和安全性监测的重要性。
研究设计与样本
- 前瞻性多中心队列研究,纳入203例维得利珠单抗和207例乌司奴单抗治疗的炎症性肠病患者。
- 维得利珠单抗组平均年龄42.2岁(标准差16.0),乌司奴单抗组平均年龄41.6岁(标准差14.4)。
- 维得利珠单抗组中位治疗时长54.0周(四分位距19.9-104.0),乌司奴单抗组48.4周(四分位距24.4-55.1)。
- 维得利珠单抗组中位随访时间104.0周(四分位距103.1-104.0),乌司奴单抗组52.0周(四分位距49.3-100.4)。
- 使用查尔森合并症指数(CCI)评估合并症,采用多变量逻辑回归调整混杂因素。
主要发现
- 维得利珠单抗治疗中,CCI独立与任何感染相关(OR 1.387,95% CI 1.022-1.883,P=0.036)。
- 维得利珠单抗治疗中,CCI独立与住院相关(OR 1.586,95% CI 1.127-2.231,P=0.008)。
- 乌司奴单抗治疗中,CCI独立与住院相关(OR 1.621,95% CI 1.034-2.541,P=0.035)。
- CCI与有效性结局无关,年龄与任何结局均无关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few data are available on the effects of age and comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD). AIMS: To evaluate the association between age and comorbidity with safety and effectiveness outcomes of vedolizumab and ustekinumab in IBD. METHODS: IBD patients initiating vedolizumab or ustekinumab in regular care were enrolled prospectively. Comorbidity prevalence was assessed using the Charlson Comorbidity Index (CCI). Association between age and CCI, both continuously assessed, with safety outcomes (any infection, hospitalisation, adverse events) during treatment, and effectiveness outcomes (clinical response and remission, corticosteroid-free remission, clinical remission combined with biochemical remission) after 52 weeks of treatment were evaluated. Multivariable logistic regression was used to adjust for confounders. RESULTS: We included 203 vedolizumab- and 207 ustekinumab-treated IBD patients, mean age 42.2 (SD 16.0) and 41.6 (SD 14.4). Median treatment duration 54.0 (IQR 19.9-104.0) and 48.4 (IQR 24.4-55.1) weeks, median follow-up time 104.0 (IQR 103.1-104.0) and 52.0 weeks (IQR 49.3-100.4). On vedolizumab, CCI associated independently with any infection (OR 1.387, 95% CI 1.022-1.883, P = 0.036) and hospitalisation (OR 1.586, 95% CI 1.127-2.231, P = 0.008). On ustekinumab, CCI associated independently with hospitalisation (OR 1.621, 95% CI 1.034-2.541, P = 0.035). CCI was not associated with effectiveness, and age was not associated with any outcomes. CONCLUSIONS: Comorbidity - but not age - is associated with an increased risk of hospitalisations on either treatment, and with any infection on vedolizumab. This underlines the importance of comorbidity assessment and safety monitoring of IBD patients.
引用
- Asscher VER, Biemans VBC, Pierik MJ, et al. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study. Aliment Pharmacol Ther. 2020. PMID: 32901983. doi:10.1111/apt.16073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。